CWBR - Earnings call transcript Q4 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon. My name is Sherry, and I will be your conference operator today. At this time, I would like to welcome everyone to CohBar’s Fourth Quarter 2019 Financial Results Conference Call. All lines have been placed on mute to eliminate background noise. [Operator Instructions] Please note this conference is being recorded.

to Investor conference Relations like Tarazi, to now of Director at would turn over the Jordyn I CohBar.

Jordyn Tarazi

results Thank everyone, you, call. financial for you, conference joining CohBar’s Sherry, fourth quarter and thank XXXX

www.cohbar.com. call me CohBar’s may were Financial issued press Cundy, Officer; Officer. is Joining XX-K Scientific website downloaded today’s Steve CohBar’s from and Officer; Chief CohBar’s Chief Biunno, Jeff and release filing earlier be Engle, our and CohBar’s today Ken Executive Chief at results on financial

having the of the website. joining you’re slide presentation access If you can issues WebEx, from CohBar’s homepage

will the business results, Jeff begin Steve quarter with update R&D of an and a fourth by overview followed from Ken. financial and

take the Before forward-looking may remind moment include to the securities within conference we like listeners meaning the laws. call begin, statements to of a remarks I’d that on today’s

but including Company’s as the delivery CBXXXX These potential therapeutic research progression statements and operations. ongoing clinical development trials not forward-looking plans drug not the its regarding expected the statements CBXXXX timing but candidate expectation limited for capital and our planned include, statements limited of the the the lead partnerships to, believe resources and potential regarding company mitochondria-based and and activities, data, to program, regarding and candidate commercial of our and are therapeutics; ability expectations and of and other drug timing CBXXXX a to fund

in number release. applicable sec.gov involve by the available our which results Safe described statements as risks with as expectations, to and on Forward-looking that statement anticipated in and today’s and from and uncertainties and our other a materially statements, those Securities regulators, and press cohbar.com, risks CohBar. with filings are included Exchange uncertainties Harbor of current that well are the sedar.com based website cause differ on and registration interpretations securities reports Canadian These could are actual projections Commission

undertake results actual a any future statements. guarantees new cautioned the information, our and of those otherwise. forward-looking events set forth publicly any from or to You in as performance are or information, that may update statements that does differ whether result not obligation such forward-looking not of or materially are future statements CohBar revise

over Chief Jeff? like Biunno, to turn Financial Jeff to Officer. CohBar’s the Now call I’d

Jeff Biunno

go Thank agenda. you, Jordyn. We’ll the now to

Next slide.

the when there’s Okay, today. a statements our fourth our up, discussion for reviewed slide Jordyn and forward-looking comes just yes, agenda that quarter here’s

a ended compared Okay, our summary now next will want a December slide to thank I $X,XXX,XXX Operating operating with provide for XXXX of $XXX,XXX this everyone $X,XXX,XXX please. in financial the and December for of Total fourth expenses joining in afternoon. of for for the to ended quarter XXXX. $XXX,XXX. XXXX to were December you QX December XX, fourth quarter expenses QX included non-cash XXXX decrease ended $XXX,XXX XX, ended compared results quarter quarter XXXX us XXXX. XX, expenses the I that’s the XX, approximately

were and depreciation the $X,XXX,XXX prior to year in decrease an expenses our development in XXXX year the QX development increase compensation These in costs. partially the of preclinical of and XXXX, expenses Decrease was compared a approximately operating non-cash peptides. the by and incurred approximately in expenses in compared that’s operating timing costs in research amortization decrease to $X,XXX,XXX $XXX,XXX. expenses, in expenses includes development due primarily Non-cash $XXX,XXX. of offset were QX related QX XXXX, to were clinical and period, expenses Net prior $X,XXX,XXX and to $X,XXX,XXX period. a total of decreases stock-based Research continuing of

of year expenses approximately year period $X,XXX,XXX and insurance decrease to due by premiums compensation current prior determination was non-cash to period, decrease administrative QX period. related General in $X,XXX,XXX in administrative to a primarily in were related an stock-based and legal prior expenses The compared costs and $XXX,XXX. XXXX, in payroll increase the severance the and partially our year in accruals, D&O on offset the incurred of CEO fees former general

CohBar and per $X,XXX,XXX to and net ended loss per the a quarter of basic $X.XX XX, Net XX, basic reported $X,XXX,XXX December loss a diluted share For for non-cash ended XX, or quarter compared of XXXX $X.XX diluted the quarter the ended XXXX. $XXX,XXX XX, December or share. and net expenses quarter December the of ended included for XXXX for XXXX, $X,XXX,XXX December loss

expenses, as December the ended XX, XX, loss ended XXXX net was December non-cash $X,XXX,XXX, the XXXX. for to CohBar’s quarter Excluding compared the quarter $X,XXX,XXX

had as XXXX. XXXX, of based balance XXXX. XX, December cash first programs. the we compared equivalents approximately that of XXXX our in investments to expenses, We on XX, have as as CohBar R&D December This million The finance certain cash ended of $XX.X in Moving cash the for of result is guidance December XXXX, materially investments and expect million XX, cash the revised December we of a was quarter our XX, delaying sheet, do which $XX.X to quarter not capital burn our to operations into estimate million. balance $X.X to and affect cash sufficient and

warrants Subsequent expiration extended to issued XX, balance data, was decided July, these the of XXXX, to in receive the Company’s date completed part to The from XXXX private XX, the in unchanged. of the XXXX. warrants the year-end, certain week next these but were the or extend of conditions paperwork remaining the the warrants as of of warrants terms offering and should company from to company. the September expect expiration Holders the two of June that

will Steve? over I Steve. call to turn now the

Steve Engle

afternoon, and today. for joining thank you us Jeff. Good everyone, Thanks,

time activities. the our our is COVID-XX It with if business. and the impede situation. the some started been news have estimate we there’s potential could disease lot possible not wanted the that this are impact could of I on note that a any monitoring get of overview, at to of on COVID-XX on like It I to companies, Before the impact most businesses

Hopefully, testing, happen, recruitment, we activities. trial if and monitoring not but related would shareholders clinical this situation the our and the update needed. are will closely monitoring example, For

conditions. and just announced our next to converted efforts In will the the meeting ROTH had changing we are be with to week, adapting Conference meetings. virtual ROTH we continuing which In the that CohBar has particular, at investors meantime,

moving So forward. we will keep

slide. Next

We have made progress recently. substantial

We oncology from looking the area And and are our up diseases. an to three we where of cancer It inhibitors. announced summer discovery many and is for programs In companies programs. is genetic approaches. for an January, this second program last new CXCRX are important pathway five

of our and preclinical in are particular area, mitochondrial clinical In have anti-fibrotic their compound in task. DNA? December, for results novel it our have supported the Why positive been a confidences finding could the mitochondria such the raises which been function millennia potent genome honed has announced we earlier benefits. positive peptides prophylactic we and results to These part peptides

certain The evolved, biological continues key functions. regulate of expand. As to are a highly technology the our result, breadth platform peptides

have and additional X one And one the in in this diabetes. all obesity, novel type cancer, fibrosis platform supports We program in two NASH peptides. potential of one and produce to the in for

Next slide.

than review of well. CohBar developing leader and ourselves DNA. there be for behind biology cells, you signals So we’ve story some are class across therapeutics learned some of powerhouses kind one Beginning the body. affects cell a finding the This the mitochondrial organs as that know in discovery item systems cornerstone for the is of that that the generate with from and technology CohBar’s that in slide the the more we may and see mitochondria

XXX like related research, discovered the multiple And of diseases over age based chronic the and genome. of has some underlies on dysfunction in the NASH others. encoded peptides mitochondria last obese mitochondria in decade and CohBar

As believe multiple we shots platform have a goal. producing result, a technology of we capable on

down at what keys we’re they a time bringing up wall them a imagine do. one out to the So XXX and on find

is is readout third humans. number evaluated technology therapeutic first data for The based CBXXXX candidates the in for is advancements that will the a the our of XXXX. study this that clinical program to expected of We of into a the first quarter in CBXXXX platform identify clinic. believe mitochondria in be

further section. in his Cundy Our Chief Officer, discuss Science Ken will this

generated and clinic we of X We new studies enabling leading In on IND planned XXXX. continuing progress programs of these one peptides entirely nominate to additional a novel in are program and type the to CXCRX our for targeting diabetes. evaluation immuno-oncology diseases, parallel, an inhibitor to fibrotic

we significant and This financial As is an experienced in as timely are to talent leveraged continues clinical portfolio strong on provides a leaders the world-class mitochondrial efficiency. based And with founders. development IP our therapeutics, by and expand. experts and research have as and team we well basis organizations, outside breadth preclinical of management

as the we quarter We’ve prudent is it rate we think We months fourth maintaining at been us stated, last our the XXXX. current end Jeff runway until the last and million few at had million plan of spending the quarter monthly As level to take of burn funds. into quarter. less additional than and expect our $X $XX.X first the to on same raise the

We to prioritize platform, on more the will we which platform spending our continue our – later. discuss

Next slide please.

There’s orchestrating been energy the of in replace not damage, adapt processes awareness and medicine. it? What cells to cells that also requirements. So systems the that aging changing environmental healthy and respond among mitochondria communicating a cells, energy mitochondria is producing of growing we’ve in role about recognition talking only within but and maintain the biological and and and to the in disease regulating and balance

therapeutic it also how approaches aging the medicine. and address systemic arena behaviors its is its what mitochondrial medical of and role of expanded role significant in affects new collectively to referring the includes mitochondrial This the we’ve diseases. and disease the very dysfunction mitochondria, needs health, to as been for It

diabetes And function example, dysfunction even potentially inflammatory about, another progresses medicine. diseases and fat and mitochondrial of immune for NASH, talked aspect the X driven cancer. mitochondrial with increasingly cirrhosis, body, by we’ve diseases downstream liver list systemic an and around and type to fibrosis, mitochondrial As of when don’t triggers mitochondria properly, obesity with dysfunction longer where processes become has starts

own seen slide. and We’ve our research activities. evidence the this development in Next of

the Our the therapeutic diseases recent our our diverse And more anti-fibrotic, research and demonstrated for earlier fibrosis. studies type obesity, even peptide originating more CXCRX And set within our peptide X diseases inflammation newer leads with that immunotherapeutic target genome. mitochondrial metabolic NASH with inflammation peptide, and and and with both diseases, metabolic all to targets, potential diabetes CBXXXX cancer. peptide research together of and

and needs dysfunction belief our range mitochondrial of wide the of broad the of library of illustrates address mitochondria the and a diversity our peptides in to supports further potential of mitochondrial diseases. roles of very This therapeutic

it mitochondrial mover in arena believe new first medicine. continues position of a important also CohBar this We incredibly as to and leader

Science Ken? our clinical progress. Chief our Officer, Ken will and preclinical Now Cundy share

Ken Cundy

on a Thank programs our program. clinical now CBXXXX R&D Steve. our give you, brief with I’ll update beginning

please. slide Next

study the is appropriate currently national testing and dose, double-blind dose obesity. Xa/Xb is ascending in Phase CBXXXX pharmacokinetics the dose involved Xb stage the safety, stage. Phase a clinical complete for single ascending to So select and healthy treatment for multiple potential Phase assessment The in of most placebo-controlled of a tolerability Xa adults as

No evaluation a in double-blind assess day designed potential significant a body restarting after biomarkers Phase tolerability were safety CBXXXX in effects This study of relevant Xb or even the subjects are weight part is to level is one obese once with NASH, metabolic observed fat, disease. the that study. of of ongoing NAFLD. obesity The phase Phase and CBXXXX and liver issues to various on Xa the placebo-controlled dose of

is stage The subjects. Phase Xb currently recruiting

be recruiting that added our to third clinical activity while sites, four sites data of new All line the appeared these study the expect of meeting expedite and now the to final when order the enrollment. quarter to with the will all a single made of and this we change are three continue fast the would We have clinical new rate. study sites enroll availability of be to open function revolve subjects criteria. site entry enough but still XXXX, it of enrollment in in unlikely top addition We timing

record by updating the will the patient ClinicalTrials.gov details be but patient changes, reflect on We enrollment. not site clinical providing be to will we

finally un-blinded when occur of the the is and after analysis of is database of reminder, is and from completion study stages Phase the study locked, Xb study As will a data the the only stage. blinded both

next at As end be call, planned, obese quarterly dosing stated will the our we progress study study milestone goes updates the the milestones. last as on NAFLD would significant the on we next If the such to update expect call. the provide of in and the last likely the subject, of on progress investor

please. slide Next

XXXX. from see biomarkers. small We Now let’s What what Phase trends treatment. readouts of we do study in we about CBXXXX. for is of talk Xb for obesity MRI-PDFF weeks said This trends involving in the next study the the to as complete plan on Phase is by with depend liver fat of data quarter national in ongoing four a we next will what third in and terms reduction Xa/Xb

not will same study of larger we outcomes or So XX the with be a X Phase longer a looking XX as duration for weeks.

In that need there select planning NASH, CBXXXX outcome, a Phase the to Based dose study design to on secondary forward, be best take need of primary are need considered. to evolving regulatory for understand and in the the development and path to the factors will number or we appropriate how Xb around regimens is regimen the and most duration landscape endpoints. we the

in the NASH for carefully need patient study consider appropriate will to right diabetes potential other the of of comorbidities We and our the population population. contribution drug, study stage to select fibrosis the most and

of toxicology, process conclude GLP-X Phase cetera. additional It preparations, advantage potential in Phase be take help advantages differentiate agonist running synergy which specifically We to et to a an the also population Xb product. consider short may our with and a includes diabetic full for manufacturing, CBXXXX need X on study to us of

as to our continue final refine also So development, commercial we a will towards form. in progress we formulation

continue these for Now of indications. outcome, potential obesity NASH and at also of the the looking all alternative factors in look other and independent our at we CBXXXX we’re to

please. Next slide

talk rest let’s pipeline. now So of about our the

have and made preclinical progress have We the the great programs now stage. last in over year we peptide four

and announced these of indications. was an recently cancer first for exciting that analogs The other new is program only MBTX

as peptides the a potent movement CXC of body. or are X CXCRX. are receptor the This and family chemokine the highly of key growth and of is of that tumors type analogs cells a immune well inhibitors regulates MBTX selective Now that chemokine as within receptor metastasis the

vivo and activity successfully The will in assays mouse detail data few family an was of more has setting this next translated in And peptides also we to model of of discuss been the in cell-based the in in vitro melanoma. slides. initial demonstrated the in aggressive

those peptides idiopathic The MBTX also that announced quarterly We in analog for on started. before today. we of fibrotic we show a some announced or last a model prophylactic our And second December, established model fibrosis in already demonstrated of therapeutic on further the mouse pulmonary had the where program We’ll MBTX efficacy IPF. IPF, efficacy is fibrosis of is diseases. shared in data has of data treatment MBTX call the previously of

program the analogs vitro. third of our analogs CBXXXX potential list program last discussed is call The the family is cells final immune the And human MBTX in cells killing of with peptide cancer receptor on Enhancing meeting. the X interacts a in XXXX by type family previously cardiovascular This involved receptor, immunotherapy. on cancer homeostasis, function diabetes. at in and family the CBXXXX peptides processes. data other presented with for of key the apelin Association Diabetes We energy American the

both considerable of interest. today’s anti-fibrotic peptides, antagonists on CXCRX the on have newest Now which the I’ll call, programs, the focus and two generated

please. slide Next

cells or the a sense Now are chemical a the are send then within make that source. can chemokine towards and cell found that of proteins move corresponding signal cell surface that receptors bone The the in key and on chemokine invasion, the CXCRX within the It in angiogenesis, and the marrow. plays cells in receptor malignant therapy. cells of the a retention role and to cancer growth, particular stem homing resistance cells also metastasis, of regulates tumor message

of cancers human cancer in This inhibition CXCRX to overexpressed cells tumors. cells, immunotherapy effect in development to mobilization surveillance. ability In chemotherapy of of tumors the and immune receptor of leads tumor blocking of the evade the of of enhances is and XX% by the reduces metastatic immune various setting

potential And CXCRX cells, be for of they has dysregulated. that is can also stem for beyond offers Now where inhibition transplantation. orphan a for potential of indications so it number mobilizing treatment harvested a CXCRX this, of

What based CXCRX a genome the to inhibitors family novel novel CXCRX of discovered peptides antagonists, that be peptide a CohBar in off mitochondrial analogs. of of target and potentially risk are has first encoded is lower effects. MBTX a that the peptides the represents offers on These

than to inhibit low low to target. potent, very MBTX minimal highly are selective the concentrations able at CXCRX and range CXCRX they’re highly Our analogs they’re the

expanded potency and showed an in in we’ve in aggressive that successfully said, of demonstrated chemotherapy I efficacy on enhancing have reducing tumors. X Analog vivo. We an As already model in at we vitro initial model was this mouse melanoma MBTX growth the effective

volume with XX% fact, alone. only In MBTX for Analog by of the the XX% combination reduced mean temozolomide tumor treatment significantly with temozolomide versus X chemotherapeutic

So let’s data more look those at detail. in

Next slide.

And tumors mice. the eight for Okay, growth to see on treatment. is animals the average here time the the in each in over this left XX the presented slide implantation after of of we

the the study. sizes individual at right, tumor you On day see the XX of

the you and rapidly. dots Now the are vehicle the grew line placebo tumors control. black And treatment with see or that can a that black,

You that does vehicle. with human not inhibitors compared as I The antibody, anti-PD-X to alone. treatment like Keytruda. immune that type tumor of resulted reduction green mouse in the which can the a see this drug line from temozolomide the line equivalent is respond the blue the said, tumor in checkpoint And agent, to about particular volume aggressive XX% a chemotherapeutic is

growth XX% and the effective. the allowing invade result of reducing to grow appears a peptide This of purple and had alone expected. Now pink particular peptide tumor MBTX But line when enhanced anti-tumor growth with the effect effect tumor resulting chemotherapy modest vehicle. the the Analog as – this CXCRX, more in in line, treatment blocking combined be in reduction the compared was with ability effect tumor it’s be the successfully temozolomide, a to the significantly to on to X tumor

left we for can all animal control vehicle group rapidly. again, individual Next And each growth see top the the black On the in study. grew very tumors in please. you curves on slide in the the that see tumor this slide,

Analog tumor can the of And a that slide. right, can pink in on received you and On the all see bottom you growth. line that animals see the that showed X MBTX bottom reduction side right the temozolomide in

please. slide Next

to program, to in So shared MBTX now and announced evidence the of our the that inhibits a the cell of transition fibrosis production fibroblasts biomarkers We myofibroblasts. that last of other on of in we the vitro the analogs. family of our cells turning This anti-fibrotic peptide MBTX process cultured is from reduces call. peptides fibrotic discovery

the anti-fibrotic observed We on those fibrosis model induction of anti-fibrotic fibrosis fibrosis. and a We effects fibrosis. was efficacy was involves model indicating positive peptide after also drug that data by until setting anti-inflammatory mouse after idiopathic treating to all saw of study pulmonary A of that on the administering shared prophylactic further bleomycin. and IPF, in therapeutic outcomes MBTX lungs extended seven anti-inflammatory effects in of had effects immediately December, model days where the Back we mouse in in the of treatment been announced delayed established the without induced.

potential of ongoing Now candidate. new other goal result activity identifying this and for that family also fibrotic drug with new peptides evaluation raises the in a of the diseases

please. with and go mouse reductions not spend shared the prophylactic fibrosis treatment we time on IPF. inflammation. previously these next I’ll MBTX data of produced Showing to much significant that Let’s model in are slide the of slide, some on this but the

please. slide Next

bars followed for established. target Here delayed green with data but has down fibrosis no slows to are anorexia. blue progression for are by and off including for given IPF. from IPF, which bars are induce bleomycin nintedanib, Clinically, The until vomiting fibrosis here it the one nausea, the of red of effects nintedanib drugs IPF, where two of fibrosis. mouse normal approved The animals The currently of out is significant the was animals placebo also are data after induction treatment model therapeutic bars was treatment.

The are purple bars MBTX.

we Here positive fibrosis, study long all on and deposition outcomes, effects saw inflammation, weight. collagen

body fibrosis. the right, lost weight also bottom we the of you after normally On can see induction preserved that that’s

And of activity goal with said, I we’re the drug other for raises as a fibrotic diseases. candidate. Now this peptide new evaluating result in the identifying potential the now

slide Let’s to go the next please.

such our overview of the first here Behind of So an both peptides high programs MBTX Phase various And cancer for clinical clinical is MBTX fibrotic R&D obesity. list for as for analogs relevant activity and a testing with to efficacy Xb preclinical of the CXCRX studies. X our data is programs expanding that slide candidate level cancer the is IPF, the and include the CBXXXX antagonist type current these MBTs. this NASH for analogs in in indications, other for immunotherapy animal CBXXXX, analogs for and diseases stage diabetes.

with And the back to hand presentation I’ll Steve. that

Steve Engle

Thanks, Ken.

ages of And NASH the with associations about patients There such of a and number that cirrhosis their want rationale I course, to few want I slide. a behind other are end in our obese. to for Americans also million cancer need. XX talk diabetes X large U.S. there obesity. take And diseases even adults There are type moment There Next are can note no million over liver at-risk to and a up with all approved disease, medical cardiovascular the a with pipeline. CBXXXX. you liver of and unmet obese XXX is of itself. And can and options the I for would begin function over drugs as liver NASH. cancer. are have lose with or NASH

space. hurdles a reduction it liver why in regulation What’s experienced fat. us. insulin is by indicated, mechanism And important represent that for the has have a other are from is unique companies CBXXXX problems companies As that in this which unlikely Ken and we the of some enhances different of is believe NASH very action, to approach the other in results

to this result, a approach maybe is a very that As novel attractive partners.

order drugs progression disease. multiple many in to the control as will require combined of likely diseases, Now fully with use NASH

than this succeed. that believe unmet compounds the compound. ours a Given we mechanisms confidence believe for in other eventually the we increase of one there’s approval Further, the more can of first room pathology, need and multiple drug high like will the category plenty of likely

fat with in would effects compounds that effects any stage now. from of Another slow liver think on be drugs right interest GLP-X who disease the that expect are to accumulation type there NASH, us marketed drugs foundational is item will as NASH. that which apparent And synergy makes CBXXXX GLP-X progress our marketing the producing because of the the event companies expected fat, be would we is at given

large with in waiting the they companies conversations year had to We’ve Xb it and pharmaceutical last and the they interested see us from to clear multiple the are that is Phase study. are results

are result, on a conservative companies. this year until able partnering a were stance the we As after we other to taking results with are the and available them share

slide. Next

behind now year. plan So talk last well Currently, we different like rationale preclinical our is I’d the the rate maintaining think to as to the as pipeline. on as burn same to it about the priorities in our programs on level programs prudent those

the initial discovery expensive evaluation are into not clinic. stages going of latter stages the the as Fortunately, and of as

Now that programs. decide the we have additional programs, how about do spending we on prioritizing

inhibitor market and as looking Currently, priority opportunity the have business several timing, CXCRX of programs. highest requirements, anti-fibrotic the R&D preclinical such factors We’re size. and the the at programs

Let me explain why.

the program, these be stem are genetic particular cell CXCRX of a and believe approved Certain which to of part compared especially working pathway, maybe on and are inhibitor inhibitor treating and in target. the also mobilization In our of We need may defects. available believe currently certain cancers. broadly companies medical analogs applicable in interesting we highly defects CXCRX cancer an and potent compound selective the as to there when is high this the CXCRX receptor, unmet for case genetic

of anti-fibrotic we And but high need not orphan. also only IPF, side IPF has indicated, preclinical general our are program and demonstrating have Ken fibrotic both range drugs in diseases approved application kidney believe with models. anti-inflammatory effects a anti-fibrotic that effects. and two broad potential both disease may as effective fibrosis have and unmet such is is As do of particularly

programs, in some of recent stage earlier In have oncology and an preclinical regards for stages like at been are diseases, development. fibrotic partnerships early indications exploring possibilities. deals potential to the of we occurring our In

Rest stage plan we very forward, still defining assets and our are anti-fibrotic activity to we to increase CXCRX outreach. indications move early of continue case, our in the the as inhibitors in we these peptides. of the and refining our partnering However, assured,

slide. Next

goals speak for goals. plan to the These let Now XXXX. me our are key

plan the of third we in the study the stage the provide complete First, to of Xa/Xb and results quarter XXXX. Xb

Second, next clinical candidate pre-IND studies our preclinical we expect into by to for four programs. identify research our continuing

and preclinical Third, financial and our we programs. clinical to invest in plan runway ability to maintain our

as in public a what course for are biotech our we So can funding. say limited of about company, we plans

However, we and conditions overall and factors money in several and clinical about which trials the ability as dealing to can market generally from data and readouts balances the maintaining to funds our strategy, our and both risk biotech, the our with invest the our speak factors globally timing, ensure amount relative such preclinical and in adequate programs cost of dilution. and

focused biotech our coverage as evaluate research cash financing gain are and we this to increasing well we Overall, institutional looking regularly our ownership framework, as Using position. needs.

results raise in in the allow of those CBXXXX maintaining and investments timing our us the the to results while program study clinical we steps take our the plan our programs. quarter, to money prior to in preclinical to to Given third continue next

monitoring we and capital investors bankers earlier, mentioned this volatility the and during the markets close contact in As recent with are in turbulent staying time.

going we expect, plan Currently, it might we but be in financing necessary. have forward, control you should As plans alternative capital prepared case are developed our changed affect we our the put if plans to haven’t costs issues place market to in plans.

base investors research and broaden anticipate to And fourth, coverage. secure that work continuing we our of

with diseases of investor funds as to roadshows hold at year Francisco. aging. in one that been chronic New the looking peers generalists institutional shares San part our looking as for solutions this and are meetings as Boston and innovative in We’ve We busy at very well the looking York, investors on and one even

days example, at the three To February. for and over over two give at JPMorgan idea, January had XX the in CEO meetings meetings days over you in during Conference an BIO we XX the meeting

we with to we changing the at efforts and the Conference conditions investors will be next mentioned, and As continuing ROTH week. our are meeting adapting virtually

we’ve response view Many the been the getting, recognized especially, of substantial investors promise of over the as peptide for no is progress from that overall this our us simply number made summer. quite idea investors, have programs an expressed from feedback longer you portfolio. we’ve give To And appreciation last in year. the increasing Many company. past NASH of different a the

and often coverage, over over of bank analyst the the Recent results inhibitor as met attention. months and technology CXCRX reception we’ve and dozen analyst past become and positive, is you with more go especially we increasing the analysts recognition as the comfortable has Regarding Street meetings the Wall involved positive multiple of a in these, opportunity. dysfunction. with anti-fibrotic impact with might our preclinical mitochondrial programs This capture generally helped expect through six their found the

on analyst often banking course, establishing coverage which on financing. a relationship, Of depends depends

anticipate discussed, technology, partnering we we after particularly have results. activities around the Xb CohBar’s As expanding

leaders mitochondrial As to development, the portfolio our expand in leadership our in to mitochondrial-based derived maintain peptide IP continue therapeutics. we

Next slide.

modulation. are realize dysfunction in illuminating the So system vision. and expand showing systems. immune They are list the derived between the multiple academic research we such mitochondria peptides metabolic. systems of as is impacts CohBar these the Recent the connections body mitochondria component of of to on mitochondria key the multiple continue Further, research on continues regulation a and new to mitochondria that and

and the from about multiple is received uniquely preclinical is five, and opportunity the has been the made well capitalize CohBar’s by potential technology these findings. potential and to of partners on prospects. increasingly goal. analysts. and CohBar has to shots investors, are enthusiastic of generate programs strong potential CohBar The substantial showing increasing team its believe the In management We fundamentals on company’s progress breath the positioned therapeutic year, the to last three peptides our scientific new platform

continue of medicine. the on mitochondrial be We front to lines

at still early full stage potential of CohBar the the realizing are vision. We the of

Now the over to I the to would like to turn line for line answers. and the questions operator open

Operator

Thank Our Private question is first Instructions] proceed. Please from Stender, you. Tom [Operator Investor.

Tom Stender

even done my more just white I wondering a answering I runway in great that always And you dropped left. of the last actually, and tell My patent it, to the Hi. to which was forward? room but can did question job relation sound job want better to why a there of the Stern – crazy, phenomenal is patents a company? And the Have Yes. me what suite. collaborations, second about is, little does elephant have question to is in the a first anybody going provisional than move anticipated. add Jon weren’t answering of to any value was this or Steven, question you but been the I

Steve Engle

compliments I’ll in Yes. the you. patent. elephant Tom, And Ken white handling talk provisional I room. the the the to Ken? appreciate let on thank

Ken Cundy

Yes.

we so do So front. you you just me? a in the what picture here Can of IP hear – have

Tom Stender

yes. Yes,

Ken Cundy

Great.

the and they area We that’s And them are with our get discovery coverage PCTs. into that of setting, we patents entire maintaining whole the assets in forward evaluate development a and right move in process the provisional we’re transformed portfolio of as will now.

Tom Stender

Yes. perfect. That’s Great.

Steve Engle

on to us me around Tom, in man time. help the So here. this in May know. was you Jon, he’s He bringing Board my is as a last get throughout been time helping And huge things in regarding And CEO here been company Jon he has right original done hand from the period. point the of

of that Now, forward helping you Jon to know area Jon has doing may we move that depth of job and still in the Investor us Jordyn Jordyn has Tarazi a kind help added I both would But IR Relations. say, effort I and recently wonderful of knowledge the there. been of with

absolutely year think I critical been in the of we’re in to make capacity we Jon’s the so comply problems. things me amount that increase And last to to happen. continuing the helping But

Operator

Private is question from Steve Caro, next Please Investor. proceed. Our

Steve Caro

of that Ken, XX our a do trial I actually hear. that problems you a question the Steve, suffering may want clinicians? and people and NASH current what candidate of on do sort run we affected can both look are how it’s question have of NASH an What you and congratulate if actually outsourced and type an to million face about into recent to from in from by people, when what on like they be these others, do Hi I number they equal United talk obesity, not getting discoveries But States greater enrollment? exciting things and and developments, explain you for your work. ignorant very of and on

Ken Cundy

question. thanks Yes. Right, the for

commitment are for studies study. it’s that in a being requires volunteer these willing me our not after also sequestered, are clarify clinical clinical a who but little case, for And part a the people for for safety patients. let They are the So in of run to time here. study of being followed-up study. end bit take of people that a your The mill the

a list, And for other patients. lot very they’re take But you at to that go meet have all exited entry those a our is what necessarily this through time to won’t in ClinicalTrials.gov also look respect a it’s doing. are volunteers on They study. asked of lot that have else willing that, they to have all criteria clean spend that come on criteria now. long if be see be so study. you’ll a off to and the And those of not listings, the I them to with So are

very the the entry taking, they’re metabolic terms One where as various they’re fat on criteria much in well. around at of of markers is, liver specific what meds how history

that’s a long just volunteers population, all of So it scooping a XX looking of is this this million reason meet can for out subjects entry is committed that criteria. XX list of not

Steve Caro

again, a – enrollment you, Thank A understanding, the just to be, follow-up for Ken. subject enrollment concern? question total would is timing

Ken Cundy

reason a decision open as One And always sites sites likely to sites. current that are Well, interrupted for having rate the well with is can. we fastest was the multiple enroll multiple that in made any to them better a of are things advantage happen is position more at if to be we going in. obviously multiple we climate

to we’ve where try third come rate So the now projection this is the right and and for taken increase at enrollment with that’s step we the quarter.

Steve Caro

Do you start have to actually have get dosing? to enrollment full to a

Ken Cundy

not the runs. This study No, a this rolling enrollment. how is is

be will come they them as we along. So enrolling

Steve Caro

help. thank Okay, Appreciate your you.

Ken Cundy

Sure.

Steve Engle

you, Steve. Thank

Operator

would remarks. management closing to no conference for the [Operator back time. over further are to I Instructions] turn like questions at this There

Steve Engle

Thanks, Sherry.

So thank you the all only couple for the progress the great for joining not us. We year. were the really whole excited made we’ve just months, today all last to of but go and news in over

tuned, and So to more thanks joining stay for come. us

Operator

today’s This you. Thank concludes conference.

your your you disconnect at for lines participation. may and thank time You the

CohBar (CWBR) 12 Mar 202019 Q4 Earnings call transcript